An analysis of survival in patients with castrate-resistant prostate cancer receiving enzalutamide with treatment breaks:
2021
Objective:Enzalutamide is effective in treating metastatic castrate-resistant prostate cancer (mCRPC) but can have side effects that require treatment breaks (TB). We conducted a retrospective anal...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
15
References
0
Citations
NaN
KQI